meta
|
evidence
COVID-19
Living systematic review and meta-analysis
adjuvant therapies
anti-inflammatoty and immuno-therapy
antiandrogenic
antiviral and associated therapy
control
Drugs for acid related disorders
miscellaneous
Oral antidiabetic drugs
Renin-angiotensin-system-acting agents
vaccines
A EFFACER BBV152 (Bharat Biotech, India)
A EFFACER Janssen Ad.26.COV2.S vaccine (JNJ-78436725)
A EFFACER_ Vero cell
A EFFACER_sequential Immunization
BCG vaccination
complete primary vaccine series
CoVLP (MT-2766, Medicago)
DNA vaccine
ebola vaccine
first booster dose
heterologous prime-boost
Inactivated virus vaccine
mRNA vaccine
Non replicating viral vector
Ad26.RSV.preF (respiratory syncytial virus)
Ad26.ZEBOV ()
Ad26.ZIKV.001 (Ad26-Vectored Anti-Zika Virus Vaccine)
CanSino (Convidecia)
Covishield (Oxford/AZ formulation)
Janssen AD26 vaccine (JNJ-78436735)
Sputnik V (Gam-COVID-Vac)
SPUTNIK-LIGHT
Vaxzevria (AstraZeneca Oxford - ChAdOx1 nCoV-19)
protein subunit vaccine
Replicating Viral Vector
seasonal influenza vaccines
second booster dose
virus-like particles vaccine
Vitamins
potential COVID-19 treatments
control
placebo
vaccines
Inactivated virus vaccine
CoronaVac (SinoVac)
mRNA vaccine
Comirnaty (tozinameran - Pfizer/BIONTECH)
All
COVID 19 hospitalized
COVID 19 all comers
COVID-19 mild to moderate
COVID-19 severe or critically
COVID 19 outpatients
COVID-19 (hospitalized or not)
COVID-19 prophylaxis (children)
COVID-19 prophylaxis (excluding children)
infections other than COVID-19
Long COVID-19
preventing respiratory virus transmission
secondary prevention
patient subgroup...
age >= 55 yr
age >= 60 yr
age >= 65 yr
age >= 75 yr
alpha variant (B.1.1.7, UK)
beta variant (B.1.351 / 501Y.V2, South Africa)
delta variant (B.1.617.2, Indian)
elderly (typically over 65yr)
positive for SARS-Cov-2 at baseline
Studies
Mapping
Meta-analysis
Excluded
Study
Exclusion reasons
Remarks
Reference(s)
Empty list - no studies excluded